1. Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
- Author
-
Kaycee M Sink, Pierre N. Tariot, Nan Hu, Yakeel T. Quiroz, Michael Malek-Ahmadi, Eric M. Reiman, Yinghua Chen, Howard Mackey, Hillary Protas, Valentina Ghisays, William Cho, Kewei Chen, Heather Guthrie, Yi Su, Dhruman D. Goradia, Claudia Muñoz, Carlos Tobon, Qinshu Lian, Paul S. VanGilder, Ji Luo, Francisco Lopera, Wendy Lee, Paula Ospina, Yamile Bocanegra, Victoria Tirado, Eliana Henao, Silvia Rios-Romenets, Pradeep Thiyyagura, Jillian Smith, Ronald G. Thomas, Jessica B. Langbaum, Margarita Giraldo-Chica, and Natalia Acosta-Baena
- Subjects
Adult ,Male ,medicine.medical_specialty ,Epidemiology ,preclinical Alzheimer's disease ,Disease ,Neuropsychological Tests ,Placebo ,Antibodies, Monoclonal, Humanized ,Presenilin ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,autosomal‐dominant Alzheimer's disease ,Cognition ,Developmental Neuroscience ,prevention ,Alzheimer Disease ,Internal medicine ,PSEN1 ,medicine ,preclinical ,Presenilin-1 ,Humans ,030214 geriatrics ,baseline data ,business.industry ,Featured Articles ,Health Policy ,crenezumab ,clinical trial ,Genetic Status ,Featured Article ,Alzheimer's disease ,Middle Aged ,Clinical trial ,Psychiatry and Mental health ,Mutation ,Alzheimer's Prevention Initiative ,Female ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,Mini-Mental Status Exam ,030217 neurology & neurosurgery - Abstract
Introduction The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo‐controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60‐year‐old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non‐carriers who receive placebo. Methods Of the 252 enrolled, we present data on a total of 242 mutation carriers and non‐carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity. Results We summarize demographic, clinical, cognitive, and behavioral data from 167 mutation carriers and 75 non‐carriers, 30 to 53 years of age. Carriers were significantly younger than non‐carriers ((mean age ± SD) 37 ± 5 vs 42 ± 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 ± 1.4 vs 29.2 ± 1.0), and had consistently lower memory scores. Discussion Although PSEN1 E280A mutation carriers in the Trial are cognitively unimpaired, they have slightly lower MMSE and memory scores than non‐carriers. Their demographic characteristics are representative of the local population.
- Published
- 2020